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Aim: Arsenic-contaminated drinking water has been associated with respiratory diseases and
lung function impairment. Oral arsenic trioxide (ATO) is a standard treatment for acute pro-
myelocytic leukaemia. This study aimed to explore the effect of therapeutic exposure to
arsenic on lung function.
Patients and method: This was a case-control cross-sectional study on patients with haemato-
logical malignancies with or without exposure to ATO. Full lung function tests and serum Clara
cell protein 16 (CC16) were measured.
Results: There were 57 cases (arsenic exposed) and 57 matched controls (arsenic non-exposed)
recruited. Among cases, the median duration of ATO exposure was 519 (194e1259) days. The
mean FEV1/FVC ratio, FEV1 (% predicted), and RV/TLC (%), as well as % subjects with FEV1/FVC
below lower limits of normal (LLN), were similar in the two groups with or without arsenic
exposure. However the mean TLC (% predicted) and DLCO/VA were significantly higher in
arsenic-exposed versus non-exposed group (pZ 0.01 and pZ 0.008 respectively). There were
mildly reduced FEV1/FVC ratio and FEF25e75 (% predicted), largely within normal limits, among
high level arsenic exposure compared with non-exposure (pZ 0.01 and pZ 0.05 respectively).
Serum CC16 was comparable among both arsenic exposed and non-exposed groups.tic leukaemia; ATO, arsenic trioxide; CC16, Clara cell protein 16; DLCO, diffusing capacity corrected
iratory flow between 25% and 75% of FVC; FEV1, forced expiratory volume in one second; FVC, forced
e; DLCO/VA, transfer factor; RV, residual volume; SD, standard deviation; TLC, total lung capacity.
t of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Special
5 4999; fax: þ852 2872 5828.
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1424 J.C.-man Ho et al.Conclusion: Therapeutic use of oral ATO for a median of around 1.5 years was not associated
with clinically significant lung function impairment.
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Arsenic is a naturally-occurring metalloid, which is noto-
rious as a deadly poison. Environmental contamination with
arsenic remains a global health problem, especially in areas
like Bangladesh [1], India [2], Pakistan [3], China [4] and
western parts of United States [5,6]. Prolonged consump-
tion of food and drinking water rich in arsenic has been
implicated as an important cause of various malignancies
(skin, urinary bladder, lung) [7e10] and non-malignant
disorders (cardiovascular diseases, peripheral neuropathy,
skin lesions) [11]. Interestingly, the impact of arsenic
exposure on lung function impairment has also only been
infrequently reported. Based on the few epidemiological
studies reported so far, decrements of lung function pa-
rameters have been found after chronic consumption of
arsenic-contaminated drinking water, particularly in people
with arsenic related skin lesions (arsenicosis) [12,13].
On the other hand, arsenic has been used medicinally for
centuries in traditional Chinese medicine, particularly in
the treatment of chronic skin conditions, parasitic in-
festations, epilepsy and asthma [14]. At the turn of the last
millennium, the clinical efficacy of arsenic trioxide (ATO)
has been confirmed worldwide in the treatment of acute
promyelocytic leukemia (APL), resulting in US Food and
Drug Administration approval of intravenous ATO (Trisenox,
Cephalon, PA, US) in this disease. However the use of
intravenous ATO has been largely limited by its toxicity and
extremely high cost. Over the past decade, an oral formu-
lation of ATO (Arsenol, Unicorn Pharma, Hong Kong) has
been developed in Hong Kong, and confirmed to be com-
parable to intravenous ATO, but with more favourable
safety profile even for prolonged use [15]. Since then, the
use of oral arsenic maintenance therapy over 2 years has
become a standard regimen for curative treatment for APL
in Hong Kong [16], eliminating the need for haematopoietic
stem cell transplantation for this condition after 1998 [17].
With the emerging therapeutic role of ATO in haemato-
logical and possibly solid malignancies, there is a pressing
need to explore the potential late adverse effects among
long-term survivors. As environmental arsenic exposure has
been suggested to have a detrimental effect on lung func-
tion, we conducted this case-control study to determine
the impact of therapeutic arsenic exposure on various lung
function indices. In addition, a serum biomarker (Clara cell
protein 16 or CC16), which has previously been found to be
an indicator of lung function impairment related to arsenic
exposure [18], was also determined.
Methods
Subject recruitment
Adult patients (18 years old) with haematological malig-
nancies on ATO treatment were recruited at Queen MaryHospital, Hong Kong from October 2010 to December 2011.
Treatment entailed oral ATO at 10 mg/day until remission,
which varied from 4 to 6 weeks. After achievement of
remission, patients received oral ATO 10 mg/day for two
weeks every two months for two years. The cumulative dose
of ATO was calculated from commencement of treatment to
timeof studymeasurements. Control subjects (1:1 ratio)with
haematological malignancies not receiving ATO, matched in
age (5 years), gender, and smoking status were also
recruited in the same haematology clinics during the
recruitment period. The exclusion criteria included known
airway diseases (asthma, chronic obstructive pulmonary dis-
ease, and bronchiectasis) prior to the diagnosis of haemato-
logical malignancies and active respiratory tract infections
within 2 weeks from the time of consent for study. All
recruited subjects have provided written informed consent.
The study protocol has been approved by the Institutional
Review Board of the University of Hong Kong/Hospital Au-
thority Hong Kong West Cluster (reference no. UW 10-382).
Clinical data collection
All study subjects (cases and controls) were interviewed by
trained research assistants with a standard questionnaire
and clinical data were also retrieved through clinic chart
review. Demographic data, relevant respiratory symptoms,
use of medications and clinical data were collected. The
amount and duration of cigarette smoking were recorded.
The presence of known airway diseases prior to haemato-
logical diagnosis was ascertained by subjects’ recall of
physician diagnosis, clinical record review or use of respi-
ratory medications. Among those with exposure to ATO, the
cumulative dose (corrected for body weight in kg) and
duration of arsenic exposure were retrieved from review of
clinic records. Serum creatinine levels were used to esti-
mate glomerular filtration rate (GRF) by Modification of
Diet in Renal Disease (MDRD) formula [19].
Lung function tests
Full lung function tests (spirometry, lung volumes and diffu-
sion)wereperformedafter informedconsentobtainedfor the
study, by a single trained technician, using the Spectra-VMAX-
22 PFT unit (SensorMedics, USA) according to American
Thoracic Society (ATS)-European Respiratory Society (ERS)
standard [20]. The different lung function indices included
FEV1 (forced expiratory volume in one second), FVC (forced
vital capacity), FEF25e75 (forced expiratory flowbetween 25%
and 75% of FVC), TLC (total lung capacity), RV (residual vol-
ume), DLCO (diffusing capacity corrected for haemoglobin),
and DLCO/VA (transfer factor). With these measurements,
obstructive lung function (reduced FEV1/FVC and FEF25e75,
with increased RV), restrictive lung function (reduced TLC)
and impaired diffusion (reduced DLCO/VA) could be deter-
mined. Available lower limits of normal (LLN) were also used,
Pulmonary toxicity of arsenic 1425in addition to % predicted values, in the interpretation of
spirometric indices. Predicted lung function reference values
were based on previous published data in Hong Kong [21,22].
Serum Clara cell protein 16 (CC16)
Venous blood samples were collected from all study subjects,
with serum stored at 70 C for subsequent assays. Serum
CC16 levels were measured using commercially availableTable 1 Demographic and clinical characteristics among
arsenic exposed and non-exposed subjects.
Arsenic
exposed
N Z 57
Arsenic
non-exposed
N Z 57
P value
Age, mean (SD) 54.8 (12.6) 52.5 (5.5) 0.21
Gender, N (%) 1.00
Male 35 (61.4) 35 (61.4)
Female 22 (38.6) 22 (38.6)
BMI, mean (SD) 25.2 (4.1) 23.5 (3.9) 0.02
Smoking status,
N (%)
0.12
Non smoker 36 (63.2) 36 (63.2)
Current smoker 3 (5.3) 9 (15.8)
Ex-smoker 18 (31.6) 12 (21.1)
Pack-year (in
ever-smokers)
n Z 21 n Z 21
Median (IQR) 20
(10.3e35.5)
16.3
(7.1e29.0)
0.22
Haematological
diagnosis, N (%)
<0.001
ALL 0 (0) 7 (12.3)
AML 0 (0) 21 (36.8)
APL 57 (100) 0 (0)
CLL 0 (0) 1 (1.8)
Lymphoma 0 (0) 9 (15.8)
Myeloma 0 (0) 13 (22.8)
Non-Hodgkin’s
lymphoma
0 (0) 3 (5.3)
MDS 0 (0) 3 (5.3)
Prior chemotherapy,
N (%)
0.48
Yes 55 (96.5) 57 (100)
No 2 (3.5) 0 (0)
Co-morbidities, N (%) 0.45
Cardiovascular 13 (22.8) 14 (24.6)
Endocrine 14 (24.6) 10 (17.5)
Bone/joint 2 (3.5) 4 (7.0)
Respiratory 2 (3.5) 0 (0)
Cancer (other
than haemic)
3 (5.3) 1 (1.8)
Others 2 (3.5) 5 (8.8)
Estimated GRF,
mean (SD)
88.47 (23.9) 95.11 (27.8) 0.18
ALL, acute lymphoblastic leukaemia; AML, acute myeloid
leukaemia; APL, acute promyelocytic leukaemia; BMI, body
mass index; CLL, chronic lymphocytic leukaemia; GFR,
glomerular filtration rate; MDS, myelodysplastic syndrome.
Statistical significance was defined as P  0.05.Human Clara Cell Protein ELISA assay kit (BioVendor, Guangz-
hou, China), according to instructions from manufacturer.
Statistical analysis
Data were presented in mean (standard deviation, SD) or
median (interquartile range, IQR) as appropriate. Depending
on data distribution, parametric (independent t-test) or non-
parametric (chi-square or ManneWhitney U ) tests were used
to test thedifferencebetweencasesand controls. Differences
in lung function indices and CC16 levels were tested between
groups with linear regression or logistic regression, where
appropriate, adjusted for age, gender, body mass index (BMI)
and smoking status. Multiple linear regressions or logistic
regression adjusted for various confounders (age, gender,
smoking status, pack-year of smoking, BMI, and duration of
arsenic use) were also performed. The high and low arsenic
exposure groups were defined by median cumulative arsenic
dose as the cut-off. All statistical analyses were performed
with SPSS V.18.0 and P  0.05 was considered significant.
Results
Demographic and clinical characteristics
From October 2010 to December 2011, there were 57
arsenic-exposed and 57 non-arsenic-exposed patients withTable 2 Lung function parameters and serum CC16 in
arsenic exposed and non-exposed subjects.
Parameters,
mean (SD)
Arsenic
exposed
N Z 57
Arsenic
non-exposed
N Z 57
P value
FVC, % predicted 107.8 (14.9) 102.3 (17.4) 0.04
FEV1, % predicted 103.9 (16.5) 99.7 (16.3) 0.15
FEV1, actual value
a
<LLN 9 (15.8%) 11 (19.3%) 0.63
LLN 48 (84.2%) 46 (80.7%)
FEV1/FVC, % 76.5 (6.7) 78.5 (6.8) 0.17
FEV1/FVC, %
a 0.39
<LLN 3 (5.3%) 6 (10.6%)
LLN 54 (94.7%) 51(89.5%)
FEF25e75, %
predicted
91.9 (29.2) 96.8 (35.7) 0.43
TLC, % predicted 102.2 (15.5) 95.7 (16.9) 0.01
RV, % predicted 98.9 (33.6) 86.6 (32.5) 0.07
RV/TLC, % 29.9 (7.0) 28.5 (8.4) 0.38
DLCO, % predicted 86.0 (18.5) 76.3 (14.6) 0.01
DLCO/VA, mmol/
kPa min/L
1.4 (0.4) 1.24 (0.3) 0.008
CC16, ng/ml 6.3 (4.2) 6.3 (3.6) 0.97
P value: linear regression or logistic regression adjusted for age,
gender, BMI, and smoking status; FVC, forced vital capacity;
FEV1, forced expiratory volume in one second; FEF25e75, mid-
expiratory flow rate; TLC, total lung capacity; RV, residual
volume; DLCO, diffusing capacity corrected for haemoglobin;
DLCO/VA, transfer factor; CC16, Clara cell protein 16.
Statistical significance was defined as P  0.05.
a Data categorized by lower limits of normal (LLN) are shown
in number of subjects (% of subjects).
1426 J.C.-man Ho et al.haematological malignancies being recruited. Among all
consecutive cases with ATO treatment (n Z 85) in our
centre during the study period, there were 28 patients who
failed to be recruited in the study due to loss of follow-up
(n Z 3), lack of interest/consent (n Z 24) and asthma
(n Z 1). Patients with arsenic exposure were comparable
with non-arsenic-exposed control subjects in demographic
and smoking status, except with higher BMI (Table 1). Since
ATO was only indicated in treatment of APL, the arsenic-
exposed cases were all having APL, while non-arsenic
exposed controls were having haematological malig-
nancies other than APL. Among the group with arsenic
exposure, the median cumulative dose and duration of ATO
exposure were 17.68 (6.89e30.18) mg/kg body weight and
519 (194e1259) days. At the time of recruitment into this
study, 46 patients (80.7%) were still continuing with ATO
treatment. For 11 patients who had stopped taking ATO,
the median (IQR) duration from last arsenic exposure was
637 (616e714) days.
Lung function indices according to arsenic
exposure
The various lung function indices (spirometry, lung volumes
and diffusing capacity) among the groups with or without
arsenic exposure are shown in Table 2. On the whole, there
was no significant impairment of lung function (using % pre-
dicted values or LLN to define normality) with arsenic expo-
sure. There were numerically higher FVC (% predicted), lungFigure 1 Correlations between cumulative dose of arsenic and lu
FEV1 (% predicted), (b) FVC (% predicted), (c) TLC (% predicted),
smoking status, pack-year of smoking, and duration of arsenic usevolume (TLC) and diffusion (DLCO/VA) among arsenic-
exposed versus non-exposed group.
Cumulative arsenic exposure and lung function
indices
Within the group exposed to arsenic, the correlation be-
tween various lung function indices and cumulative dose of
ATO is depicted in Fig. 1. There was no correlation between
the key lung function parameters (pre-bronchodilator FEV1,
FVC, TLC and DLCO/VA) and cumulative dose of ATO.
Defining the level of arsenic exposure into low (at or below
median cumulative dose of 17.68 mg/kg body weight,
broadly equivalent to total dose of arsenic administered in
1.5 years) and high (above median cumulative dose of
17.68 mg/kg body weight) dose, multiple regression anal-
ysis demonstrated a significantly lower FEV1/FVC ratio and
FEF25e75 (% predicted) in high dose versus non-exposure
group but significantly higher TLC, RV and DLCO/VA in low
dose versus non-exposure group (Table 3). Using LLN as cut-
off value for normality, the spirometric indices were similar
among low or high dose arsenic exposure groups compared
to control (Table 4).
Serum Clara cell protein 16 (CC16) and arsenic
exposure
The serum CC16 levels were similar among groups with or
without exposure to arsenic (Table 2). Based on linearng function indices (for cases with arsenic treatment only): (a)
(d) DLCO/VA. P: Adjusted for age, gender, body mass index,
.
T
a
b
le
3
M
u
lt
ip
le
re
gr
e
ss
io
n
a
n
a
ly
si
sa
o
f
th
e
e
ff
e
ct
o
f
cu
m
u
la
ti
ve
a
rs
e
n
ic
e
xp
o
su
re
o
n
lu
n
g
fu
n
ct
io
n
a
n
d
se
ru
m
C
C
16
.b
P
a
ra
m
e
te
rs
,
m
e
a
n
(S
D
)
N
o
e
xp
o
su
re
to
a
rs
e
n
ic
(N
Z
57
)
A
rs
e
n
ic
lo
w
d
o
se
(
17
.6
8
m
g/
kg
)
(N
Z
29
)
A
rs
e
n
ic
h
ig
h
d
o
se
(>
17
.6
8
m
g/
kg
)
(N
Z
28
)
P
M
e
a
n
d
if
fe
re
n
ce
c
(9
5%
C
I)
P
0
M
e
a
n
d
if
fe
re
n
ce
d
(9
5%
C
I)
P
00
F
V
C
,
%
p
re
d
10
2.
30
(1
7.
39
)
10
7.
21
(1
4.
48
)
10
8.
46
(1
5.
58
)
0.
19
7.
39
(
0.
36
to
15
.1
3)
0.
06
5.
15
(
5.
63
to
15
.9
4)
0.
35
F
E
V
1
,
%
p
re
d
99
.7
4
(1
6.
30
)
10
4.
97
(1
5.
22
)
10
2.
93
(1
7.
95
)
0.
35
6.
15
(
1.
66
to
13
.9
6)
0.
12
1
.5
6
(
12
.4
3
to
9.
31
)
0.
78
F
E
V
1
/F
V
C
,
%
78
.4
9
(6
.8
2)
77
.5
9
(5
.6
2)
75
.3
2
(7
.5
3)
0.
13
1
.2
9
(
4.
34
to
1.
77
)
0.
41
5
.4
4
(
9.
69
to
1
.1
9)
0
.0
1
F
E
F
2
5
e
7
5
,
%
p
re
d
96
.8
1
(3
5.
66
)
96
.7
2
(2
4.
24
)
86
.9
3
(3
3.
34
)
0.
38
2
.4
8
(
18
.4
8
to
13
.5
3)
0.
76
2
2.
81
(
45
.0
9
to
0
.5
3)
0
.0
5
T
LC
,
%
p
re
d
95
.6
7
(1
6.
94
)
10
3.
38
(1
5.
94
)
10
0.
96
(1
5.
10
)
0.
09
10
.8
2
(2
.8
1
to
18
.8
3)
0
.0
0
9
7.
00
(
4.
49
to
18
.4
8)
0.
23
R
V
,
%
p
re
d
86
.5
6
(3
2.
54
)
10
6.
03
(3
6.
93
)
91
.1
5
(2
8.
17
)
0
.0
4
19
.2
9
(2
.6
3
to
35
.9
5)
0
.0
2
4.
31
(
19
.5
9
to
28
.2
0)
0.
72
R
V
/T
LC
,
%
28
.4
7
(8
.3
6)
31
.0
0
(7
.0
4)
28
.7
6
(6
.9
6)
0.
34
2.
56
(
1.
05
to
6.
18
)
0.
16
0
.5
1
(
5.
70
to
4.
67
)
0.
85
D
LC
O
/V
A
,
m
m
o
l/
kP
a
m
in
/L
1.
24
(0
.2
6)
1.
42
(0
.3
2)
1.
39
(0
.3
7)
0
.0
2
0.
13
(0
.0
03
to
0.
25
)
0
.0
5
0.
16
(
0.
01
to
0.
34
)
0.
07
C
C
16
,
n
g/
m
l
6.
29
(3
.6
2)
6.
88
(4
.5
1)
5.
79
(3
.8
7)
0.
59
0.
78
(
1.
01
to
2.
58
)
0.
39
0.
46
(
2.
01
to
2.
93
)
0.
71
St
a
ti
st
ic
a
l
si
gn
ifi
ca
n
ce
w
a
s
d
e
fi
n
e
d
a
s
P

0.
05
.
a
A
d
ju
st
e
d
fo
r
ag
e
,g
e
n
d
e
r,
b
o
d
y
m
as
s
in
d
e
x,
sm
o
ki
n
g
st
at
u
s,
p
ac
k-
ye
ar
o
f
sm
ok
in
g,
an
d
d
u
ra
ti
on
of
ar
se
n
ic
u
se
;a
rs
e
n
ic
lo
w
d
os
e
w
as
d
e
fi
n
e
d
as
cu
m
u
la
ti
ve
d
os
e
1e
17
.6
8
m
g/
kg
;
ar
se
n
ic
h
ig
h
d
os
e
w
as
d
e
fi
n
e
d
as
cu
m
u
la
ti
ve
d
o
se
>
17
.6
8
m
g/
kg
;
P
va
lu
e
w
as
ca
lc
u
la
te
d
w
it
h
th
e
A
N
O
V
A
te
st
.
b
C
la
ra
ce
ll
p
ro
te
in
16
.
c
T
h
e
m
e
a
n
d
if
fe
re
n
ce
(9
5%
C
I)
a
n
d
P
0 v
a
lu
e
re
fe
r
to
co
m
p
ar
is
o
n
o
f
a
rs
e
n
ic
lo
w
d
o
se
ve
rs
u
s
n
o
n
-e
xp
o
su
re
in
th
e
a
d
ju
st
e
d
m
o
d
e
l.
d
T
h
e
m
e
a
n
d
if
fe
re
n
ce
(9
5%
C
I)
a
n
d
P
0v
a
lu
e
re
fe
r
to
co
m
p
ar
is
o
n
o
f
a
rs
e
n
ic
h
ig
h
d
o
se
ve
rs
u
s
n
o
n
-e
xp
o
su
re
in
th
e
a
d
ju
st
e
d
m
o
d
e
l.
Pulmonary toxicity of arsenic 1427regression analysis, serumCC16was not associatedwith any
of the key lung function indices (pre-bronchodilator FEV1/
FVC ratio, FVC, TLCandDLCO/VA) after adjustment for age,
gender, BMI, and smoking status. Similarly, there was no
difference in serum CC16 levels between high or low cu-
mulative arsenic exposure compared with non-exposure
group (Table 3).Discussion
To our knowledge, this is the first ever reported case-
control study investigating the role of therapeutic arsenic
exposure on lung function. Because of the unique avail-
ability of oral arsenic formulation in our institution for
clinical use, it allows proper study of the impact of
defined cumulative arsenic exposure on lung function
indices. As Hong Kong is not subject to environmental
threat of arsenic contamination (drinking water arsenic
level <0.001 mg/L from October 2010to September 2011,
data from http://www.wsd.gov.hk/en/water_resources/
water_quality/water_quality_monitoring_data/index.
html, last accessed on 20 Nov 2012), there is little con-
founding effect from dietary consumption of arsenic. Our
findings showed a lack of detrimental effect of thera-
peutic exposure to arsenic trioxide on spirometric indices,
lung volumes and diffusion. The exposure to therapeutic
arsenic, especially with low cumulative level, was asso-
ciated with higher lung volumes and diffusion.
The current knowledge about the probable link be-
tween arsenic exposure and lung function decrement is
largely derived from sparse epidemiological studies on
populations exposed to arsenic-contaminated drinking
water. The first population-based study was conducted in
West Bengal of India, involving a source population of 7683
subjects from the initial survey of arsenic skin lesions [13].
Based on a subgroup of 287 subjects with lung function
assessed by portable spirometry, it was found that men
with arsenic skin lesions had significantly lower adjusted
FEV1 (256.2 ml less) and FVC (287.8 ml less) compared to
those without skin lesions. Similarly in a more recent case-
control cross-sectional study of 200 subjects conducted in
Pakistan, there was significantly a reduced mean adjusted
FVC (221.9 ml), trend of reduced mean adjusted FEV1
(154.3 ml) and preserved FEV1/FVC ratio among arsenic
exposed compared to unexposed groups [12]. On the other
hand, an earlier case-control study based on spirometry
has suggested mainly obstructive (68.9%) lung function
impairment with chronic arsenic exposure [23]. The other
studies suggesting the association between arsenic expo-
sure and non-malignant respiratory diseases were largely
based on mortality data and symptomatology, instead of
proper lung function assessment, which could be prone to
various confounding factors. Notably, chronic arsenicosis
has been associated with increased prevalence of chronic
cough, chronic bronchitis, shortness of breath, chest
sounds on examination, and bronchiectasis [24e28].
Apart from lung function tests, our study has also
incorporated the measurement of a biomarker for respi-
ratory epithelial injury, namely serum CC16. Previous
studies have indicated a protective role of CC16 against
inflammation and oxidative stress in respiratory tract [29].
Table 4 Logistic regression analysisa of the effect of cumulative arsenic exposure on lung function by lower limits of normal
(LLN).
Parameters, N (%) No exposure
to arsenic
(N Z 57)
Arsenic low dose
(17.68 mg/kg)
(N Z 29)
Arsenic high dose
(>17.68 mg/kg)
(N Z 28)
P ORb
(95%CI)
P0 ORc
(95%CI)
P00
FVC, actual value
<LLN 6 (10.5) 2 (6.9) 1 (3.6) 0.52 4.73
(0.41e54.99)
0.22 5.51
(0.46e65.72)
0.18
LLN 51 (89.5) 27 (93.1) 27 (96.4)
FEV1, actual value
<LLN 11 (19.3) 3 (10.3) 6 (21.4) 0.48 2.06
(0.35e12.10)
0.42 0.36
(0.04e3.41)
0.37
LLN 46 (80.7) 26 (89.7) 22 (78.6)
FEV1/FVC, %
<LLN 6 (10.5) 1 (3.4) 2 (7.1) 0.51 3.16
(0.26e37.98)
0.36 0.37
(0.02e6.10)
0.48
LLN 51 (89.5) 28 (96.6) 26 (92.9)
FEF25e75, actual value
<LLN 7 (12.3) 3 (10.3) 4 (14.3) 0.90 0.97
(0.19e4.96)
0.97 0.36
(0.04e2.89)
0.33
LLN 50 (87.7) 26 (89.7) 24 (85.7)
Data categorized by LLN are shown in number of subjects (% of subjects).
a Logistic regressions were adjusted for age, gender, body mass index, and smoking status; arsenic low dose was defined as cumulative
dose 1e17.68 mg/kg; arsenic high dose was defined as cumulative dose >17.68 mg/kg; P value was calculated with the Chi-square test.
b OR (95% CI) and P0 value refer to comparison of arsenic low dose versus non-exposure in the adjusted model.
c OR (95% CI) and P0 value refer to comparison of arsenic high dose versus non-exposure in the adjusted model.
1428 J.C.-man Ho et al.So far, there has been only a single study investigating the
role of CC16 in arsenic-related lung function impairment
[18]. Serum CC16 has been shown to be inversely related to
urinary arsenic concentrations especially among individuals
with arsenic skin lesions. From a subgroup of 31 subjects
with spirometric assessment, urinary arsenic concentration
was inversely associated with predicted FEV1, and those
with low lung function (predicted FEV1 and FVC) tended to
have lower serum CC16 [18].
These previous epidemiological studies were limited by
several important factors, including recall bias and influ-
ence of arsenical skin lesions on symptomatic perception.
Also, common respiratory symptoms were non-specific. The
quantification of the exact amount of arsenic exposure was
also subject to error in previous studies, as it was mostly
based on a cross-sectional measurement of arsenic con-
centration in drinking water and the assumption of the
same level of consumption over the years. Among those
studies with pulmonary function measurements, only
spirometry was performed without determination of proper
lung volumes and diffusion.
Our findings of a lack of significant lung function
impairment with therapeutic exposure to arsenic should be
encouraging for long-term survivors of acute promyelocytic
leukaemia. The clinical significance of lower FEV1/FVC ratio
and FEF25e75 with high level of arsenic exposure remains to
be determined, especially largely above LLN. The apparent
discrepancy of our results from previous studies suggesting
reduced pulmonary function with chronic arsenic exposure
could be due to several putative mechanisms. Firstly, the
detrimental impact of arsenic on pulmonary function may
only be limited to in utero or early childhood exposure
[30,31]. Secondly, the prolonged duration (for decades) of
arsenic exposure might be crucial to the long-term impact
on lung function. It is of note that therapeutic oral-ATO is
given at a standard dose of 10 mg daily for consecutive 2weeks and stopped for 6 weeks in each cycle, to be
continued for a total of 2 years. This is in contrast to the
continued and prolonged arsenic exposure from environ-
mental sources. Environmental arsenic exposure was also
frequently estimated indirectly from urinary arsenic con-
centrations, suggesting that prolonged low-dose arsenic
accumulation might have occurred. In our cohort of pa-
tients, blood arsenic levels were instead evaluated [32],
and showed a rapid decline to baseline levels after cessa-
tion of ATO treatment. However, the possibility of accu-
mulation of arsenic in tissues could not be excluded.
Thirdly, the therapeutic use of arsenic in the formulation
known as “Fowler’s solution”, first recognized in the Lon-
don Pharmacopoeia of 1890, was well-known for treating
severe asthma as indicated in the 11th edition (in 1989)
Merck index [14,33]. Interestingly, recent animal models
have also suggested a therapeutic role of arsenic trioxide in
alleviating airway hyperresponsiveness and eosinophilia
[34,35]. Therefore, the short-term therapeutic use of
arsenic trioxide as in our cohort may even potentially
improve the pulmonary function.
The exact mechanisms how arsenic can potentially exert
non-malignant pulmonary effects are not fully elucidated,
possibly related to tissue inflammation, reduced humoral
and mucosal immune responses, oxidative stress and pul-
monary fibrosis [23,36,37]. On the other hand, the mech-
anisms for our observed findings of numerically higher lung
volumes and diffusion (by % predicted) with therapeutic
arsenic exposure remain to be explored.
There are several limitations of our study. First, the
sample size of cases (n Z 57) is relatively small. However,
as ATO is only indicated in treatment of APL, we believe
this is probably the largest reported cohort of therapeutic
use of ATO with lung function measurements. Second, this
is a cross-sectional case-control study, in which there is
lack of baseline lung function data prior to ATO treatment.
Pulmonary toxicity of arsenic 1429A prospective longitudinal lung function study can better
address the impact of therapeutic ATO exposure on lung
function changes. Third, therapeutic exposure to ATO, in
contrast to long-term environmental exposure to arsenic,
may have different effects on organ functions. Therefore,
we would caution direct extrapolation of our findings on
therapeutic to environmental arsenic exposures.
In conclusion, therapeutic use of oral ATO for a median
duration of around 1.5 years is not associated with clinically
significant impairment of pulmonary function. Short of
prospective data during ATO treatment, our findings are
probably the best available lung function data for thera-
peutic exposure to ATO. Subsequent longer-term follow-up
lung function study in our cohort will allow better under-
standing of the late-effects of therapeutic exposure to
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